about
Exciting directions in glaucomaLatrunculin B Reduces Intraocular Pressure in Human Ocular Hypertension and Primary Open-Angle Glaucoma.Intra-ocular pressure-lowering effects of a Rho kinase inhibitor, ripasudil (K-115), over 24 hours in primary open-angle glaucoma and ocular hypertension: a randomized, open-label, crossover study.Bioengineered glaucomatous 3D human trabecular meshwork as an in vitro disease model.Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms.Biomechanics of Schlemm's canal endothelium and intraocular pressure reduction.Emerging drugs to treat glaucoma: targeting prostaglandin F and E receptors.The many faces of the trabecular meshwork cell.Investigational and experimental drugs for intraocular pressure reduction in ocular hypertension and glaucoma.Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.Comparative Study of the Effects of Trabecular Meshwork Outflow Drugs on the Permeability and Nitric Oxide Production in Trabecular Meshwork Cells.Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension.Proteasome Inhibition Increases the Efficiency of Lentiviral Vector-Mediated Transduction of Trabecular Meshwork.Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma.Modulation of Schlemm's canal endothelial cell stiffness via latrunculin loaded block copolymer micelles.The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans.
P2860
Q28542397-E8499B34-DC4E-4912-8666-968C43E60E7AQ34181305-601C8A80-9C7D-45BE-970D-448A2B88B665Q34452693-9B324AC9-280F-4232-B601-9028192DF41BQ36863008-8FA64612-4485-4BD6-87C1-A605A825CD40Q37420927-56B7E5CA-3455-434D-BAC6-EDA6ECC4063EQ38249883-52389640-7BD2-48F9-A4FA-AEA74F7761C5Q38725839-1A8B1ACB-BECC-4FE7-BFD7-B3285C017CB3Q38904598-89A43854-6AF4-4AAA-AFA4-7C5692E7E8B4Q38934012-2ACF0ECA-C17E-4551-B99C-0045015D906FQ38963936-9DD965A9-C58F-4EEB-B7E5-AC0F1B985E7EQ42262056-E035FDE9-95B6-4792-AFAE-A557624B6B73Q46154462-3467E736-C942-4B6E-9B24-CD187F160AC2Q47552653-FB5F9CA0-8B1B-4946-B7B6-9E98938C77E4Q50947105-5078C4ED-F5A5-4128-8C6B-D6FF7D320EF9Q51738820-239AD7F2-4A82-4981-8975-5B2E642EDA7BQ52690602-6B2074FF-ECD5-4F2D-8310-13D17714D38E
P2860
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Emerging trabecular outflow drugs.
@en
Emerging trabecular outflow drugs.
@nl
type
label
Emerging trabecular outflow drugs.
@en
Emerging trabecular outflow drugs.
@nl
prefLabel
Emerging trabecular outflow drugs.
@en
Emerging trabecular outflow drugs.
@nl
P2860
P356
P1476
Emerging trabecular outflow drugs.
@en
P2093
Casey C Kopczynski
David L Epstein
P2860
P356
10.1089/JOP.2013.0197
P577
2013-12-04T00:00:00Z